Mirum Pharmaceuticals (MIRM)

• Market cap: $3.73B
• 1 day: -0.16%
• 5 days: -3.23%
• 1 month: 9.22%
• 3 months: 47.14%
• 6 months: 64.32%
• Year to date: 76.47%
• 1 year: 83.55%
• 5 years: 250.95%
• 10 years: 461.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Employees: 349

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

15% more capital invested

Capital invested by funds: $2.44B [Q1] → $2.82B (+$375M) [Q2]

1.35% more ownership

Funds ownership: 110.47% [Q1] → 111.83% (+1.35%) [Q2]

3% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 33

0% less funds holding

Funds holding: 213 [Q1] → 212 (-1) [Q2]

5% less repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 80

18% less funds holding in top 10

Funds holding in top 10: 11 [Q1] → 9 (-2) [Q2]

69% less call options, than puts

Call options by funds: $1.55M | Put options by funds: $5.06M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $77
• Avg. target: $83
• High target: $89

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Jessica Fye	$77	Overweight Maintained	12 Sep 2025
Stifel Dae Gon Ha	$89	Buy Reinstated	11 Aug 2025
Evercore ISI Group Gavin Clark-Gartner	$89	Outperform Maintained	8 Aug 2025
JMP Securities Jonathan Wolleben	$81	Market Outperform Maintained	7 Aug 2025
Raymond James Steven Seedhouse	$82	Strong Buy Maintained	7 Aug 2025